CORDIS
EU research results

CORDIS

English EN

AIDS VACCINE INTEGRATED PROJECT

Project information

Grant agreement ID: 503487

  • Start date

    1 February 2004

  • End date

    31 January 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 15 748 493

  • EU contribution

    € 10 300 000

Coordinated by:

ISTITUTO SUPERIORE DI SANITÀ

Italy

Objective

Vaccines based on viral structural products (Env/Gag/Pol) alone have failed to prevent infection by HIV/SIV. Vaccines based on viral regulatory gene products (Tat/Rev/Nef) have contained virus replication preventing disease onset.A vaccine combining both (combined vaccine) is likely to be superior to the formers since it induces immune responses targeting both early and late viral products. The mission of AVIP is to develop novel preventive and therapeutic vaccines to be tested in phase I trials in Europe, that are suitable for future testing in phase II/III trials in Developing Countries (DC), and to foster training, technology transfer and community involvement among EU and DC.

To ensure completion of the program, priority has been given to vaccine combinations containing single antigens that are already approved for human use and in phase I studies and with proven efficacy in animal models.Therefore, AVIP specific objectives are to conduct:
1.Preventive and therapeutic phase I trials in Europe with 4 novel combined vaccines. These will be first tested in preclinical models to optimise the formulation and the vaccination protocols, and then will enter phase I trials.
2.Feasibility studies and technology transfer in DC for future phase II/III trials within the European and Developing Countries Clinical Trials Programme (EDCTP).
3.Training in EU countries and DC. To this goal, the AVIP International School will be established.
4.Community involvement both in EU countries and DC to ensure the correct ethical information of the volunteers, counselling, quality of life evaluation and risk assessment. AVIP objectives will be implemented by an ad hoc management structure which will oversees the science, training, business and administrative activities of AVIP.

Coordinator

ISTITUTO SUPERIORE DI SANITÀ

Address

Viale Regina Elena 299
Rome

Italy

Participants (18)

KAROLINSKA INSTITUTET

Sweden

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

FIT BIOTECH OYJ PLC

Finland

HELMHOLTZ CENTER MUNICH, GERMAN RESEARCH CENTER FOR ENVIRONMENTAL HEALTH

Germany

NOVARTIS VACCINES AND DIAGNOSTICS SRL

Italy

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

WITS HEALTH CONSORTIUM (PTY) LTD

South Africa

UNIVERSITY OF STELLENBOSCH

South Africa

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

Italy

HEALTH PROTECTION AGENCY

United Kingdom

TERRAMATICA CONSULTING SRL

Italy

UNIVERSITY OF THE WITHWATERSRAND, JOHANNESBURG (MEDICAL RESEARCH COUNCIL, AGINCOURT)

South Africa

MINISTRY OF HEALTH (NATIONAL REFERENCE LABORATORY - MBABANE)

South Africa

COMMISSARIAT À L'ÉNERGIE ATOMIQUE

France

UNIVERSITÀ DEGLI STUDI DI MILANO

Italy

UNIVERSITÀ DEGLI STUDI DI PADOVA

Italy

UNIVERSITÀ DEGLI STUDI DI URBINO "CARLO BO"

Italy

UNIVERSITÀ DI FERRARA

Italy

Project information

Grant agreement ID: 503487

  • Start date

    1 February 2004

  • End date

    31 January 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 15 748 493

  • EU contribution

    € 10 300 000

Coordinated by:

ISTITUTO SUPERIORE DI SANITÀ

Italy